C
앱클론
174900KOSDAQ48.5 / 100
Reference Date: 2026-10-23
Financial Score15.0 / 40
News Sentiment12.5 / 25
Momentum9.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 11.5% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Appclone is a biotech company specializing in the development of monoclonal antibody-based pharmaceuticals. It focuses on creating 'Biosynergy' drugs that enhance efficacy when combined with existing medications and 'Biounique' antibodies with distinct mechanisms of action for monotherapy. The company also leverages its 'Affibody' technology and human antibody library to develop innovative treatment solutions.
Number of Employees
66people
Average Salary
57.9M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
7.53Industry Average 1.200.0Point
6.3x industry avg (risky)
ROE
-39.86Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
1.58Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲41.4% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼23.5% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -45.9% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (8%, downtrend)
Current 22,800Won52-week high 89,10052-week low 16,820
1-month return5.0Point
1m +11.49% (rising)
Volume trend3.0Point
Volume flat
Detailed Disclosure
1 totalPositive 1Neutral 0Negative 0
- Positive[기재정정]단일판매ㆍ공급계약체결(자율공시)2026-09-30